Brothers Austin, 14, and Max, 11, both have a rare genetic disease called Duchenne Muscular Dystrophy (DMD), a fatal condition characterized by progressive muscle degeneration and weakness due to lack of dystrophin, a protein that helps preserve muscle cells.
A new drug, currently in the trial phase, shows promise in stabilizing the disease and even allowing health improvement. However, only Max qualified for the trial because he is still walking. Max has experienced significant health gains during the past 18 months. Austin can only look on from his wheelchair as his physical condition continues to deteriorate.
Most people with DMD die by age 20.